In: Cellular and Molecular Life Sciences, 2015, vol. 72, no. 4, p. 659-671
|
In: Viruses, 2020, vol. 12, no. 1, p. 17 p
Human cytomegalovirus (HCMV) infects more than 70% of the human population worldwide. HCMV is responsible for high morbidity and mortality in immunocompromised patients and remains the leading viral cause of congenital birth defects. Despite considerable efforts in vaccine and therapeutic development, HCMV infection still represents an unmet clinical need and a life-threatening disease in...
|
(Working Papers SES ; 509)
Vaccine development is a lengthy, expensive and risky venture, with the research and development (R&D) process costing billions of dollars. The pre-clinical stage of vaccine R&D is largely performed by academic research institutions, then continued by the pharmaceutical industry though licensing agreements, taking the most promising candidates to the clinical testing stage. Governments play a...
|
In: Proceedings of the national academy of sciences of the United States of America, 2014, vol. 111, no. 50, p. 17965-17970
The use of neutralizing antibodies to identify the most effective antigen has been proposed as a strategy to design vaccines capable of eliciting protective B-cell immunity. In this study, we analyzed the human antibody response to cytomegalovirus (human cytomegalovirus, HCMV) infection and found that antibodies to glycoprotein (g)B, a surface glycoprotein that has been developed as a HCMV...
|
In: Current Infectious Disease Reports, 2010, vol. 12, no. 3, p. 181-185
|
In: Antonie van Leeuwenhoek, 2008, vol. 93, no. 1-2, p. 185-192
|
In: European Journal of Pediatrics, 2009, vol. 168, no. 11, p. 1343-1348
|
